The Global Emphysema Treatment Market is Predict to reach $6.05 Billion by 2028, at a CAGR of 6.1%

Published Date: 21-Feb-2023

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Emphysema Treatment Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Emphysema Treatment size is expected to reach $6.05 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.

The Steroids market is showcasing a CAGR of 6.8% during (2022 - 2028). Inhalational or oral administration of corticosteroids, such as prednisone, are both viable options for treating steroid-related conditions. In order to identify whether or not a patient has emphysema in their sputum, a physician may sometimes do tests on the patient, such as obtaining a sample of the patient's sputum. If they do, the steroid therapies may work better for them.

The Drug Stores & Retail Pharmacies market acquired maximum revenue share in the Global Emphysema Treatment Market by Distribution Channel in 2021, thereby, achieving a market value of $3.2 billion by 2028. In the emphysema treatment market in 2021, the bronchodilators segment accounted for the largest revenue share. The expansion of this market segment may be attributed to an increase in the demand for bronchodilators as a therapy for emphysema and increased knowledge about the condition.

The North America market dominated the Global Emphysema Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2.7 billion by 2028. The Europe market is registering a CAGR of 6.6% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 7.1% during (2022 - 2028).

Full Report:

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma PLC

Global Emphysema Treatment Market Segmentation

By Medication Type

  • Bronchodilators
  • Steroids
  • Others

By Distribution Channel

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Viatris, Inc.
  • Orion Corporation
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Hikma Pharmaceuticals PLC
  • Boehringer Ingelheim International GmbH
  • Verona Pharma Plc

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

North America Emphysema Treatment Market Future Scope & Opportunities 2022-2028

Europe Emphysema Treatment Market Size & Growth Forecast 2022-2028

Asia Pacific Emphysema Treatment Market Size, Share & Industry Outlook to 2028

LAMEA Emphysema Treatment Market Growth, Trends & Forecasts 2022-2028

Request a Free Sample Copy

Why Choose Us

  • 24/7 Research support
    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Information security
    Your personal and confidential information is safe and secure.